Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been given an average recommendation of “Moderate Buy” by the five ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) Director Garen G. Bohlin acquired 41,140 shares of Karyopharm Therapeutics stock in a transaction dated Tuesday, September 12th. The stock was bought at an average price of $1.22 per share, with a total value of $50,190.80. Following the completion of the purchase, the director now directly owns […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.